Multistep alterations of chromosome 17 in the progression of human urinary bladder neoplasia were studied by superimposed histologic and genetic mapping. The p53 gene was included in the analysis as a model tumor suppressor gene that is frequently involved in urothelial carcinogenesis. The strategy provided a systematic approach to the study of multistep genomic alterations that occur as neoplasia progresses from precursor intraurothelial conditions to invasive cancer. This was accomplished by sampling the entire mucosa of the organ and displaying microscopically identi®ed invasive cancer and precursor conditions in the form of a histologic map. Subsequent isolation of DNA provided a set of samples in which the search for genetic alterations was performed and superimposed on the histologic map. This approach disclosed multifocal allelic losses of chromosome 17 in the early preinvasive phases of urothelial neoplasia. The alterations were predominantly con®ned to the p12 ± 13, q22 ± 11 and q24 ± 25 regions. Mutations and allelic losses of the p53 gene were mapped to early preinvasive phases of urothelial neoplasia. The data provide detailed analysis of chromosome 17 allelic losses that occur in the development and progression of urothelial neoplasia and represent the ®rst step for genome-wide modeling of multistep human urothelial carcinogenesis.
Introduction
Genomic mapping with polymorphic markers, such as microsatellites, provides a useful tool for studying disorders in which genetic predisposition plays an important role in pathogenesis of the disease (Cohen et al., 1993; Gyapay et al., 1994; Leach et al., 1993; Stallings et al., 1990; Thibodeau et al., 1993; Weissenbach et al., 1992) . These markers are particularly useful in familial syndromes in which the subsequent generations of one family carry a distinct germ cell abnormality (Collins, 1992 (Collins, , 1995 . They are less informative when used to study sporadic diseases, such as most human cancers, in which multiple genomic alterations are involved (Collins, 1992 (Collins, , 1995 . In such instances, the conventional linkage analysis on the basis of pedigrees is not possible, and the search for genetic changes is restricted to a comparison of tumor and normal host DNA samples. In the case of multiple alterations that develop in a sequential or cumulative pattern via several pathways, this approach usually produces inconclusive data in which the primary changes may not be distinguishable from secondary alterations.
Here, we present a strategy to study genomic alterations using superimposed histological and genetic mapping. With this approach, the markers are not only tested on paired tumor versus normal host DNA samples, but they are also related to the progression of neoplasia from precancerous lesions to invasive cancers. This is accomplished by a sampling of the entire mucosa of an organ. The distribution of a microscopically identi®ed invasive cancer and its precursor conditions are then displayed in the form of a histologic map. Subsequent isolation of DNA generates a set of samples in which the search for genetic alterations with various probes can be performed and the results can be superimposed over the histologic map. We have tested this strategy on human radical cystectomy specimens with invasive carcinoma.
At the time of diagnosis, most invasive carcinomas of the urinary bladder are accompanied by extensive precursor lesions that range from mild dysplasia to carcinoma in situ (Koss et al., 1974 (Koss et al., , 1977 Koss, 1979) . In human urinary bladder carcinomas, alterations of chromosome 17 have been shown to have a particularly strong correlation with high histologic tumor grade and invasive growth potential (Dalbagni et al., 1993a,b; Olumi et al., 1990; Presti et al., 1991; Tsai et al., 1990) . In this report, we present patterns of microsatellite alterations on chromosome 17 in relation to the progression of urinary bladder neoplasia from intraurothelial precursor lesions to invasive carcinoma as revealed by superimposed histologic and genetic mapping. The same approach was utilized to reveal the alterations (allelic losses and mutations) of the p53 gene. The p53 gene was included in this analysis as a model tumor suppressor gene with a well-established role in human urothelial carcinogenesis and a postulated association with muscle invasive growth (Spruck et al., 1994; Sidransky et al., 1991) . Several mathematical models were used to analyse the data, including conventional chisquare contingency tables and receiver-operating characteristic (ROC) analysis. In addition, the organization of our data permitted the use of LOD scores to determine whether speci®c loci on chromosome 17 could be implicated in the development and progression of urothelial neoplasia.
Results

Histologic maps
Histologic mapping of the entire urinary bladder mucosa was performed on ®ve human cystectomy specimens with invasive transitional cell carcinoma (TCC). Four cases (maps 1, 2, 4, and 5) had a single focus of grade 3 nonpapillary TCC invading into the muscularis propria. The tumors were accompanied by extensive precancerous lesions that ranged from mild dysplasia to carcinoma in situ. In one case (map 3), multiple foci of TCC were present. One focus represented a grade 3 papillary TCC with transmural invasion of the bladder wall and involvement of the perivesical adipose tissue. Two additional foci represented grade 3 papillary TCC without invasion. Similar to the other four cases, extensive areas of the urinary F Figure 1 Histologic map of urinary bladder mucosa in case A with a single focus of grade 3 invasive nonpapillary transitional cell carcinoma. (A) Gross photograph of open cystectomy specimen shows an ulcerated tumor on the posterior wall. A plastic grid with 162 cm rectangular perforations was superimposed over the specimen to facilitate sampling as described in Materials and methods. Microscopic appearances of urothelium in hematoxylin and eosin stained frozen sections of (B) normal urothelium (C) moderate dysplasia, (D) severe dysplasia and (E) carcinoma in situ. (F) Histologic map of cystectomy specimen shown in (A) Map code: (1) urothelium with mild hyperplasia and no microscopically recognizable dysplasia, (2) mild dysplasia, (3) moderate dysplasia, (4) severe dysplasia, (5) carcinoma in situ and (6) invasive carcinoma. White (blank) areas within the histologic map designate areas with denuted urothelium. (B-E: H&E stain6200) Superimposed histologic and genetic mapping V Chaturvedi et al bladder mucosa in this case exhibited changes that ranged from mild dysplasia to carcinoma in situ. Figure  1 is an example of a histologic map of the entire urinary bladder showing an area involved by invasive carcinoma and the distribution of intraurothelial precursor lesions.
Superimposed histologic and genetic maps
The initial testing of paired normal and tumor DNA samples from the same patient revealed alterations in 18 out of 38 tested markers on chromosome 17. The alterations consisted of loss of heterozygosity (LOH) and homozygotic deletions. No abnormally sized (shortened or expanded) alleles of repetitive sequences were identi®ed. The summary of tested markers, their alterations, and chromosomal locations are provided in Figure 2 . Testing of alterations on multiple samples from the same patient revealed the same pattern of allelic loss, i.e. the same allele was always altered (lost), indicating that a clonal relationship existed among the samples with the altered marker ( Figure 3 ). The superimposition of microsatellite alterations over the histologic maps disclosed two basic patterns of chromosome 17 deletions: scattered (in a form of several isolated foci) and plaque-like ( Figure 4) . Some of the plaque-like alterations involved large areas of urinary bladder mucosa with various precursor conditions, including low-grade intraurothelial neoplasia, and some areas of morphologically normal urothelium. These ®ndings indicated that the alteration occurred early in the process of urothelial neoplasia. Alterations of some other markers were restricted to speci®c stages of neoplasia, e.g. invasive carcinoma or invasive carcinoma with adjacent carcinoma in situ, which indicated an association with late phases of the process and invasive growth. Figures  5 and 6 show the relation between microsatellite alterations on chromosome 17 and the progression of urothelial neoplasia from intraurothelial precancerous changes to TCC in individual cases. Each case had a distinct pattern of chromosome 17 alterations. The three separate foci of TCCs in map 3 also showed distinct patterns of microsatellite alterations.
Superimposed histologic and genetic mapping of p53 Table 1 is a summary of the p53 alterations identi®ed in ®ve cystectomy specimens. Allelic losses of the TP53 marker located within the p53 gene and of adjacent microsatellite D17S960 were identi®ed in one case (map 5). Mutations of exons 6, 7, and 9 were present in three cases (maps 3, 4, and 5, respectively). In one case (map 5), both the mutation of exon 6 and the allelic deletions of TP53 and D17S960 were found. In two cases (maps 3 and 4), the mutation of the gene was not associated with its allelic losses. In the remaining two cases (maps 1 and 2), no alterations of p53 could be documented. Superimposed histologic and genetic mapping revealed plaque-like alterations of p53 mutations or allelic losses in the three cases ( Figure 6 ). The alterations involved invasive carcinoma and large areas of urinary bladder mucosa with intraurothelial precursor conditions. Our data indicated that, in all three cases, p53 alterations could be mapped to early stages of intraurothelial neoplasia consistent with low-grade intraurothelial neoplasia. In map 5, allelic loss and exon 6 mutation involved almost the entire urinary bladder mucosa, which exhibited various (low-and high-grade) intraurothelial precursor conditions. These ®ndings indicated that both types of alterations (i.e. mutation and allelic loss) occurred early in the carcinogenesis process. Moreover, separate foci of TCC in map 3 exhibited the same mutation of p53 that was also present in the areas of intraurothelial precursor conditions involving the bladder mucosa among the tumors (data not shown). 
Data analysis
Chi-square or ROC analysis revealed that the alterations of four markers (D17S849, D17S786, D17S933 and D17S807) and mutations of p53 could be related to the development and progression of urothelial neoplasia. In reference to several markers, the ROC area below the ROC curves could not be calculated. In addition, several chi-square analyses were performed using contingency tables, with a marginal number of samples required to obtain meaningful calculations. Both chi-square and ROC analyses most likely underestimated the involvement of chromosome 17 markers in urothelial neoplasia and thus did not seem to be proper methods with which to analyse this type of data (Table 2) .
LOD scores provided more detailed analyses of chromosome 17 alterations ( Figure 7 ). The markers with statistically signi®cant patterns of LOD scores could be related to several distinct regions of chromosome 17: p12 ± 13 (TP53, D17S960, D17S786, D17S799 and D17S947), q21 ± 11 (D17S579, D17S932 and D17S934), q22 (D17S943) and q24 ± 25 (D17S807 and D17S784). Alterations of markers D17S786, D17S799, D17S947, D17S579, D17S932, D17S943 and D17S807 represented the earliest detectable changes to chromosome 17 and mapped to low-grade urothelial neoplasia and adjacent areas of microscopically normal urothelium. At least three distinct regions on chromosome 17 seemed to be consistently involved ± in multistep fashion ± in urothelial neoplasia. Within these regions, the number of altered markers with signi®cant LOD score patterns increased as neoplasia progressed to high-grade intraurothelial neoplasia ( Figure 8 ). However, in the chromosomal regions q12 ± 13 and q21 ± 11, the number of altered markers with statistically signi®cant LOD scores decreased in foci of TCC compared with areas of high-grade intraurothelial neoplasia. This decrease could be arti®cial because signi®cantly fewer TCC samples were available for calculations compared with the number of samples of preneoplastic conditions. On the other hand, if this result is accurate, then additional deletions of chromosome 17 do not play a major role in the development of invasive phenotypes in tested cases. Allelic losses and mutations of p53 were mapped to early stages (low-grades) of urothelial neoplasia. Statistically signi®cant LOD scores for allelic losses and mutations of p53 were obtained in both levels of stringency for low-and high-grade intraurothelial neoplasia.
Discussion
Our strategy of superimposed histologic and genetic mapping discloses a unique pattern of chromosome 17 alterations that can be related to the development and This approach discloses multiple alterations of chromosome 17 even in early preinvasive phases of urothelial neoplasia. Some of these alterations can be identi®ed in areas of microscopically normal urothelium, indicating that they precede the development of morphologically recognizable changes. The alterations progress in a cumulative multistep fashion as neoplasia progresses. Although some distinct patterns of chromosome 17 alterations existed in each case, the changes seem to preferentially involve several chromosomal regions (p12 ± 13, q21 ± 11 and q24 ± 25). In these regions, the number of signi®cantly altered markers increased in relation to progression of neoplasia from early (low-grade) to late (high-grade) intraurothelial precursor conditions. On the other hand, our data suggest that the additional allelic losses in these regions are not a major factor in the development of the invasive phenotype. Alterations of the p53 gene (mutation and allelic loss) were mapped to early phases of urothelial neoplasia. LOD score analysis con®rmed the important role of this tumor suppressor gene in the development and progression of urothelial neoplasia. It is well known that SSCP is not perfectly reliable to identify mutations. Since it was used in our study as an initial screening test to identify potential mutations of the p53 gene which were subsequently con®rmed by sequencing, the possibility that the presence of p53 mutations which were not documented in two cystectomy specimens (maps 1 and 2) cannot be entirely ruled out. Overall it appears that chromosome 17 is the target of essentially haphazard and cumulativè hits' in urothelial carcinogenesis, some of which eect the p53 gene.
The ®rst histologic maps of human cystectomy specimens were generated approximately 20 years ago and provided the basis for the so-called`dual-track concept' of the development of urinary bladder cancer (Koss et al., 1974 (Koss et al., , 1977 Koss, 1979; Koss and Czerniak, 1991) . This concept implies that common urothelial tumors arise via two distinct but sometimes overlapping pathways, one that leads to papillary TCC and another that leads to nonpapillary (solid) TCC (Czerniak et al., 1992; Cairns et al., 1994; Spruck et al., 1994) . Approximately 80% of urothelial tumors are super®cially growing papillary TCCs that may recur but that usually do not invade or metastasize (Czerniak et al., 1992; Czerniak and Herz, 1995; Koss, 1995) . Most invasive carcinomas are nonpapillary and arise from intraurothelial precursor lesions (dysplasia) and carcinomas in situ that have developed either as primary lesions or as lesions accompanying papillary tumors (Koss et al., 1974 (Koss et al., , 1977 Koss, 1979) . Lowgrade papillary TCCs have fewer chromosomal changes than do high-grade carcinomas, particularly regarding trisomies of chromosomes 1 and 7 and deletions of chromosome 9 (Spruck et al., 1994; Czerniak and Herz, 1995) . On the other hand, highgrade invasive bladder carcinomas develop multiple cumulative rearrangements and deletions of chromosomes with formation of marker chromosomes, which frequently involve chromosomes 3, 11, 17, and 18 (Chang et al., 1995) . Deletions of chromosome 17 in the p11 ± 13 region which contains putative tumor suppresser genes are frequently observed in TCCs of high histologic grade and advanced stage (Dalbagni et al., 1993a) . More recently, deletions of chromosomes 8p21 ± q11.2, 4p16.3, 9p21, and 14q which also contain putative tumor suppressor genes, have been postulated to play an important role in the pathogenesis of bladder carcinoma (Chang et al., 1995; Elder et al., 1994; Knowles et al., 1993; Miyao et al., 1993; Ruppert et al., 1993; Mao et al., 1994; Kolberg, 1993) . On the molecular level, invasive high-grade nonpapillary TCCs of the urinary bladder are more likely to develop alterations in multiple transforming and tumor Figure 1F . Open boxes delineated by black lines indicate areas of urinary bladder mucosa with alterations in a given locus. White areas within the histologic map designate regions with no data (not enough DNA for ampli®cation, denuded urothelium ulceration with in¯ammatory cells, etc) suppressor genes than are super®cial low-grade papillary lesions (Czerniak and Herz, 1995; Dalbagni et al., 1993b) .
Alterations of microsatellites in human cancer range from LOH through homozygotic deletions to expansion or shortening of their repetitive sequences LGIN, low-grade intraurothelial neoplasia; HGIN, high-grade intraurothelial neoplasia and TCC, transitional cell carcinoma. In case C, three separate foci of carcinoma are designated as follows: two separate foci of grade 3 noninvasive papillary carcinoma (T 1 and T 2 ) and invasive grade 3 papillary carcinoma (T 3 ). Open circles indicate samples with no alteration in a marker. Solid black circles designate samples with alterations in a given locus. Note the presence of the same mutant p53 in three dierent foci of transitional cell carcinoma Superimposed histologic and genetic mapping V Chaturvedi et al (Eshleman and Markowitz, 1995) . The latter is referred to as microsatellite instability and is typically observed in cancers such as familial nonpolyposis colonic carcinoma, which arises in association with malfunctioning DNA-repair genes (Wooster et al., 1994) .
Occasionally it can also be present in selected loci in sporadic neoplasia that is unrelated to any known DNA-repair gene (Uchida et al., 1995; Yee et al., 1994 ; (E) Superimposed histologic and genetic map of p53 mutation (map 5, exon 6). Note that both mutations and allelic loss involve large areas of adjacent mucosa with intraurothelial precursor conditions. Code for histologic map is the same as that in Figure 4 Superimposed histologic and genetic mapping V Chaturvedi et al Gonzalez-Zulueta et al., 1993) . In some sporadic cancers, microsatellite instability occurs with an increased frequency in more advanced stages of neoplastic disease (Yee et al., 1994; Gonzalez-Zulueta et al., 1993) . Unstable microsatellites have been identi®ed in selected loci on chromosome 9 in fewer than 5% of sporadic bladder carcinomas (GonzalezZulueta et al., 1993) . This change appears to be common in those bladder carcinomas that occur in a clinical setting of familial non-polyposis colonic carcinoma (Lynch II syndrome) (Linnenbach et al., 1994) . The strategy of superimposed histologic and genetic mapping expands the applicability of polymorphic markers to the study of multistep genomic alterations in the development and progression of neoplasia from clinically occult precancerous lesions to invasive cancer, however, the strategy has two potential limitations. First, it requires multiple tests (an average of 200 ± 300 tests have to be performed on one chromosome per cystectomy specimen) and consequently only a limited number of cases can be studied with this strategy. Second, mucosal DNA samples may be contaminated by DNA from the attached stromal tissue, and in some samples, allelic imbalance can be masked by a signal from normal host DNA. These limitations, however, can be easily overcome by careful tissue dissection of microscopically veri®ed samples for DNA extraction and by automated laboratory procedures.
In general, the strategy of superimposed histologic and genetic mapping allows a systematic analysis of multistep genomic alterations in the progression of neoplasia from precursor conditions to invasive cancer. It permits the use of powerful mathematical models of maximum likelihood binomial analysis framed as LOD scores to test the multistep involvement of speci®c chromosomal loci and genes in sporadic cancers. Furthermore, this approach can be used with a variety of probes and techniques to study the development of alterations in already identi®ed loci or genes. A similar strategy can be applied to study other human and animal neoplasias that are associated with microscopically recognizable precursor conditions.
Materials and methods
Cystectomy specimens
Radical cystectomy specimens from four male and one female patients (maps 1 ± 5) who had previously untreated high-grade invasive TCC of the bladder were prepared as follows.
(1) The bladder was opened longitudinally along the anterior wall and pinned down to a paran block. (2) A plastic grid with holes was superimposed over the specimen and each 162 cm rectangle of the mucosa was individually pinned down. (3) After the removal of the plastic grid, the entire bladder mucosa was separated into individual 162 cm samples and evaluated under a microscope for histologic changes on frozen sections. For microscopic evaluation of urothelium, a single histologic section was prepared from each 162 cm area and was stained with hematoxylin and eosin. (4) DNA was extracted from each sample using a nonorganic DNA extraction kit (ONCOR). The tissue of interest was identi®ed microscopically and initially microdissected from the frozen block. DNA was extracted from cell suspension containing approximately 90% of microscopically recognizable urothelial cells. The cell suspensions were prepared by mechanical stripping of urothelium from microdissected samples with a razor blade. Samples which contained less pure cell suspensions were not included in the analysis and are shown in histologic maps as blank areas. This procedure provided 49, 39, 65, 42 and 39 DNA samples, respectively, from each bladder. To compare the microsatellite allelic patterns, DNA was also extracted from the peripheral blood lymphocytes of each patient. The intraurothelial precancerous changes were classi®ed as mild, moderate and severe dysplasia and carcinoma in situ. Urothelial samples classi®ed as normal urothelium occasionally exhibited mild hyperplasia or reactive change but showed no microscopically recognizable dysplasia. The TCCs were classi®ed according to the three-tier histologic grading system of the World Health Organization (Koss, 1995) . Their growth pattern (papillary versus nonpapillary or solid) and depth of invasion were also recorded. The histologic sections were evaluated independently by two pathologists (JYR and BC). 
Microsatellites
A set of 33 microsatellite markers for the chromosome 17 loci were selected from an updated Genethon microsatellite map (Gyapay et al., 1994) . Another ®ve microsatellite markers that were not included on the Genethon map were also tested (Swift et al., 1995; Cropp et al., 1994) . All primers were purchased from Research Genetics. The markers selected for testing exhibited high levels of heterozygosity and relatively uniform distribution, i.e. covered all regions of chromosome 17, including those which are of special interest to urothelial carcinogenesis. Microsatellite loci were tested by polymerase chain reaction (PCR). PCR was done in a 10 ml reaction volume containing 50 ng of template DNA, 200 mM of each deoxynucleoside triphosphate, 2.5 mCi of 32 P-labeled deoxycytidine triphosphate, 0.3 mM of each primer, and 0.6 U of Taq polymerase. PCR products were resolved on 6% polyacrylamide urea gel for 2 h at 55 W. Radiograms were visually examined for loss of heterozygosity (LOH). In questionable cases, densitometric measurements were performed and at least 50% of signal intensity reduction was considered as evidence of LOH. Initially, all the microsatellite loci were tested on paired tumor and normal host DNA samples extracted from an invasive carcinoma and peripheral blood lymphocytes of the same patient. Microsatellite loci identi®ed as altered during this initial testing were selected for superimposed histologic and genetic mapping of the entire urinary bladder mucosa. Approximately 2000 tests were performed to reveal the patterns of alterations to chromosome 17 and their relationship to the progression of urothelial neoplasia.
Superimposed histologic and genetic maps
The positions of mucosal samples and their microscopic changes were recorded and displayed in the form of histologic maps. The superimposed histologic and genetic maps were generated by custom-designed software. The data consisted of a vector of chromosome 17 with microsatellite positions, their alterations, and coordinates for locations of the samples. The results were displayed by superimposed histologic and genetic maps that showed the areas of bladder mucosa with an altered microsatellite locus and its relationship to precancerous intraurothelial conditions and TCCs. In addition, the data were presented using the two-vectors technique. In this display, a vector with microsatellite positions was related to the tissuedesignation vector, which showed the progression of urothelial changes from normal urothelium through dysplasia to carcinoma in situ and invasive cancer.
Superimposed histologic and genetic mapping of p53
Allelic loss of p53 was tested with two markers, DS17960 and TP53. Point mutations of exons 5 ± 9 were tested by single-strand conformational polymorphism using the following primers:
exon 5: 5'-TTCCTCTTCCTGCAGTACTC-3', 5'-ACCCTGGGCAACCAGCCCTGT-3' exon 6: 5'-ACAGGGCTGGTTGCCCAGGGT-3', 5'-AGTTGCAAACCAGACCTAT-3' exon 7: 5'-GTGTTGTCTCCTAGGTTGGC-3', 5'-GTCAGAGGCAAGCAGAGGCT-3' exon 8: 5'-TATCCTGAGTAGTGGTAATC-3', 5'-AAGTGAATCTGAGGCATAAC-3' and exon 9: 5'-GCAGTTATGCCTCAGATTCAC-3', 5'-AAGACTTAGTACCTGAAGGGT-3'.
These sets of primers ampli®ed 244, 184, 189, 213, and 137 bp fragments of exons 5 through 9 respectively.
Oligonucleotide primers for the single-strand conformational polymorphism were synthesized with an Applied Biosystems DNA/RNA synthesizer (model 392, Perkin Elmer Cetus) following the manufacturer's recommended procedure. Genomic DNA (100 ± 150 ng) was ampli®ed by PCR with 40 ng of each primer, 200 mM of each dNTP, 1 mCi of [a-32 P]dCTP (Amersham; speci®c activity, 3000 Ci/ mmol), 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 0.01% gelatin, and 1 U of Taq polymerase (Perkin Elmer Cetus) in a ®nal volume of 10 ml. The ampli®cation reaction consisted of 34 cycles of 1 min at 948C, 1 min annealing at 558C (exons 5, 6, 7 and 9) or 588C (exon 8) and 2 min at 728C for extension. The reaction mixture was diluted (1:10) in 0.1% sodium dodecyl sulfate to 10 mM EDTA and then mixed 1:1 with a solution containing 95% formamide, 20 mM EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol. Samples were heated to 908C for 5 min, chilled on wet ice and resolved on a 6% polyacrylamide: Tris-borate-EDTA gel containing 10% (v:v) glycerol for 17 h at 6 W.
Initially the markers DS17960 and TP53, as well as mutations of exons 5 ± 9 of p53, were tested on paired tumor and normal host DNA samples, extracted from a TCC and from peripheral blood lymphocytes of the same patient. Markers with alterations and exons exhibiting mutations were selected for superimposed histologic and genetic mapping. To con®rm the presence of a mutation identi®ed by single-strand conformational polymorphisms, direct sequencing of PCR-generated gene fragments were performed using the Sequenase PCR Product sequencing kit (United States Biochemical Corp), according to the protocol supplied by the manufacturer.
Statistical analysis
For the purpose of statistical analysis the intraurothelial precancerous changes were classi®ed into two major groups: low-grade intraurothelial neoplasia (mild and moderate dysplasia) and high-grade intraurothelial neoplasia (severe dysplasia and carcinoma in situ). The relationship among alterations of the markers and urothelial neoplasia was tested by the chi-square contingency tables, ROC analysis and LOD score tests. For the purpose of the analysis of our data, the ROC and LOD score tests were performed as follows.
In a typical ROC analysis a tested parameter is compared with another variable that represents a`gold standard' (Swets and Pickett, 1982) . In our data the tested parameters represent the alterations of the markers compared with the microscopic identi®cation of the urothelial changes. This yielded a 264 contingency table (f ji , j=1,2; i=1, . . .,4). The columns designated whether the marker was unchanged or changed and the four grades represented the microscopic status of the urothelium (D 0 normal urothelium, D 1 lowgrade intraurothelial neoplasia, D 2 high-grade intraurothelial neoplasia, and D 3 , TCC). To calculate the ROC curve, three contingency subtables were formed summing the columns below a cuto i (D 0 , . . . ,D i ± 1 ), and above (D i , . . ., D 3 ) for i=1, . . ., 3. For each table the false-negative fraction (FNF), true negative fraction (TNF), false-positive fraction (FPF) and true positive fractions (TPF) were calculated as:
Typically, an ROC curve is a plot of FPF on the x axis and TPF on the y axis augmented with the two end points (0,0) and (1,1) from which a curve is estimated on the basis of probit theory (Metz, 1989) . The analysis of our data was performed by plotting the complement TNF versus FNF. This provided a deviation of the ROC curves from the guess line in agreement with the progression of neoplasia by placing normal urothelium in the lower left and TCC in the upper right of the curve. The ROC analysis was performed with the use of the ROCFIT program by Metz (1989) . The signi®cance of the areas below the ROC curves versus the guess line were examined by a t-test. The dierences among the areas of the ROC curves were tested by the Tukey multiple comparison test at P=0.05.
For the LOD score analysis, the data were organized using the same 264 table. For each category of urothelial status (D i ; i=0, . . .,3) the maximum likelihood for the binomial distribution was used to determine whether a row of data was consistent with a hypothesis of an unchanged (all negative) marker by calculating the log likelihood with l i ln (1) after adjustment by 2 ln(10)=4.605. . . . Because the maximum likelihood estimates for the individual rows are usually dierent from each other, the sum of the LOD scores and the sum of the chi-squares were greater than the combined statistics. A chi-square test for heterogeneity was appropriate to test the combined estimate (Zar, 1996) . Usually y i =0.5 is used to test linkage in familial disorders with meiotic segregation of the phenotype (Ott, 1991) . In reference to sporadic cancer and especially when populations of tested cells represent sequential stages of the process with mitotic transmission of the phenotype the null hypothesis is more appropriately veri®ed at y diering from 0.5. For example, a value of 0.99 is more appropriate if the marker is unchanged in the tissue, and a value of 0.01 is more appropriate for determining whether the marker has been altered from an unchanged to a changed state in the later stages of the process, i.e. invasive carcinoma. Consequently, patterns of LOD score values as shown and described in Figure 7 are used to evaluate the relationship between an altered marker and various phases of neoplasia and their progression. It has to be understood that the use of LOD scores in this analysis is not the same as that commonly used in linkage analysis of familial genetic predisposition for diseases and is intended to be used in its generic mathematical sense as likelihood tests of events. We used the LOD score variant of the likelihood test as many researchers are more familiar with approximate levels of signi®cance when expressed in this form.
